Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 40

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 40
---
 in such equity sale. Related Agreements In connection with the Merger, the parties entered into several agreements, namely, a Management Services Agreement, an Intellectual Property License Agreement, a Voting & Support Agreement and a Stockholders Agreement, each of which are included as an Annex to this proxy statement/prospectus. While the entities themselves are parties to the agreements, certain individuals at DiamiR may have additional interests. Dr. Sheinerman is a managing director at H.C. Wainwright & Co., LLC (“Wainwright”), with which DiamiR has a financial advisory agreement pursuant to which Wainwright acts as exclusive financial advisor to DiamiR in connection with the Merger. Additionally, Dr. Kira Sheinerman owns less than one percent (1%) of Aptorum’s Class A ordinary shares and will be appointed to the Combined Company’s board of directors. Dr. Mireskandari and Mr. Anthony, DiamiR’s current Chief Executive Officer and Chief Financial Officer, will also be appointed the Combined Company’s executive management, as Chief Operation Officer and Chief Financial Officer, respectively. Management Services Agreement At the time of the execution of the Merger Agreement, Aptorum Therapeutics and DiamiR entered into a management services agreement pursuant to which Aptorum Therapeutics shall pay a monthly service fee of $87,500 to DiamiR and reimburse expenses to DiamiR in exchange for the officers and employees of DiamiR providing services to Aptorum Therapeutics to develop a diagnostic test for early detection and monitoring of progression of glioblastoma until the earlier of the closing of the Merger or December 31, 2025 in the following positions, subject to change as set forth in the agreement: Alidad Mireskandari, President or Chief Executive Officer; Gary Anthony, Comptroller or Chief Financial Officer; Gyanendra Kumar, V.P. of Assay Development; Kenny Ablordeppey, Director of Assay Development; Jacob Goldman, Data Scientist; and Sydney Finkelstein, Medical Director. 3 Intellectual Property License Agreement At the time of the execution of the Merger Agreement, DiamiR, DiamiR LLC and Aptorum Therapeutics Limited entered into that certain Limited Interim Patent and Know -HowLicense Agreement (the “Intellectual Property License Agreement”) pursuant to which DiamiR and DiamiR LLC shall license on a non -exclusivebasis their respective intellectual properties to the Company in exchange for upfront and periodic payments until the earlier of the closing